

**NEGATIVE FORMULARY COMMITTEE
ORLANDO AIRPORT MARRIOTT
7499 AUGUSTA NATIONAL DRIVE
ORLANDO, FL 32822
(407) 851-9000
SEPTEMBER 26, 2009
10:00 A.M.**

Board Members:

Cynthia Griffin, PharmD
Steve Melvin, PharmD
Lorena Risch, Consumer Member
Jason Rosenberg, MD
Elizabeth Tucker, MD
Gary Winchester, MD

Board Staff:

Larry McPherson, JD, Executive Director
Rebecca Poston, RPh, Executive Director
Crystal Sanford, CPM, Program Administrator
Maxine Wenzinger, Administrative Assistant II

Board Counsel:

Diane Guillemette, JD
Ed Tellechea, JD

Call to Order

- TAB 1 Approval of Minutes from June 20, 2007**
- TAB 2 Election of Chair and Vice-Chair**
- TAB 3 Mylan Pharmaceutical, Inc. Submission to the Negative Drug Formulary Committee in Support of the Removal of Levothyroxine Sodium from Florida's Negative Drug Formulary**
- TAB 4 Abbott Laboratories Submission in Response to the Petition by Mylan Pharmaceuticals, Inc., Seeking the Removal of Levothyroxine Sodium from Florida's Negative Drug Formulary**
- TAB 5 Presentation- Clinical Concerns Regarding Removal of Levothyroxine from the Negative Drug Formulary- Eliot G. Levy, MD**
- TAB 6 Correspondence Received from Interested Parties**
- 1. American Thyroid Association- Barbara Rath Smith, CAE**
 - 2. National Association of Chain Drug Stores- Dale Masten**
 - 3. Paul S. Denker, MD FACE**
 - 4. The Light of Life Foundation, Inc- Joan Shey**
 - 5. Sandoz, Inc.- Ron Hartmann, RPh, MBA**
 - 6. Presentation- Clinical Concerns Regarding Removal of Levothyroxine from the Negative Drug Formulary- Elliot G. Levy, MD**
 - 7. Wal-Mart Health and Wellness Division- Tim Koch, RPh**
 - 8. Joseph D. Howard, MD**
 - 9. Nikhita Dhruv, MD**
 - 10. Vera Endocrine Associates, Inc- Arnold Vera, MD, MSC, FACE, CDE**
 - 11. CVS Caremark Corporation- Michael J. Ayotte, R.Ph.**
 - 12. Generic Pharmaceutical Association- Gordon Johnston, RPh., MS**
 - 13. Gainesville Endocrine and Diabetes Associates, PA- John I. Jones III, MD, FACE**
 - 14. Jennifer Ricihardson, Physician Assistant**
 - 15. Steve Bast, MD**

TAB 7

Reference Material

- **2007 Mylan Pharmaceuticaqls, Inc, Petition**
- **Rule 64B16-27.500, F.A.C., Negative Drug Formulary**
- **Section 465.026, F.S. Substitution of drugs**
- **Section 465.0251, F.S. Generic drugs; removal from formulary under specified circumstances**